Beryl Drugs Limited has submitted its quarterly compliance certificate to the Bombay Stock Exchange, fulfilling regulatory requirements under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The filing pertains to the quarter ended March 31, 2026, and was submitted on April 7, 2026.

Regulatory Compliance Filing

The compliance certificate was filed under Regulation 40(9) of SEBI regulations, which mandates listed companies to submit periodic reports regarding share transfer activities. Chairman & Director Sudhir Sethi signed the submission letter, while Company Secretary Dipika Kataria issued the compliance certificate.

Share Transfer Activity

The compliance certificate confirms that no share transfer activities occurred during the quarter ended March 31, 2026. Company Secretary Dipika Kataria certified that no share transfer forms were received during the financial year period, and consequently, no share certificates were processed.

Certificate Issuance Status

The certificate also confirms that no certificates were issued for sub-division, consolidation, renewal, exchange, or endorsement of calls/allotment monies during the reporting period. This indicates minimal corporate action activity during the quarter.

Company Information

Beryl Drugs Limited maintains its registered office at 133 Kanchan Bagh, Indore, Madhya Pradesh. The company's share transfer activities are managed by Adroit Corporate Services Private Limited as the registrar and transfer agent. The compliance certificate was issued by Company Secretary Dipika Kataria, who holds membership number 8078 and certificate of practice number 9526.

Beryl Drugs Limited has completed the filing of its quarterly compliance reports with the Bombay Stock Exchange for the quarter ended March 31, 2026. The pharmaceutical company submitted the required documentation on April 6, 2026, ensuring adherence to various regulatory obligations under the Securities and Exchange Board of India framework.

Compliance Reports Filed

The company filed three essential compliance certificates as mandated under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015:

Depositories Compliance Confirmation

Adroit Corporate Services Private Limited, serving as the company's Registrar and Share Transfer Agent, provided detailed confirmation regarding dematerialisation activities during the quarter. The agent confirmed that all securities received from depository participants for dematerialisation were properly processed and confirmed to the depositories within the stipulated timeframe.

The compliance certificate specifically states that security certificates received for dematerialisation were mutilated and cancelled after due verification by the depository participant. Additionally, the names of the depositories were substituted in the register of members as registered owners within the mandatory 15-day period.

Non-Applicability Declaration

In the official filing, Beryl Drugs confirmed that Regulation 57(5) is not applicable to the company since there are no non-convertible securities for which interest, dividend, or principal is payable during the quarter ended March 31, 2026. This declaration was made in accordance with SEBI compliance requirements for listed companies.

Share Transfer Facility Maintenance

Under Regulation 7(3) of the SEBI LODR Regulations, Beryl Drugs confirmed that activities related to both physical and electronic share transfer facilities were maintained throughout the period from April 01, 2025 to March 31, 2026. The company's share transfer operations are managed by Adroit Corporate Services Private Limited.

Corporate Information

The timely filing of these compliance reports demonstrates Beryl Drugs' commitment to maintaining regulatory standards and transparency in its operations as a publicly listed pharmaceutical company.